PRESS RELEASES
10 April 2024
Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024
22 September 2022
Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip
18 May 2022
Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology
19 April 2022
Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader
17 January 2022
Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics
08 January 2022
Dr. Allen, VP of Anticancer Bioscience, presented his insights on personalized / precision medicine at a roundtable discussion organized by Pharma’s Almanac
20 December 2021
Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China
25 October 2021
Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon Review
14 October 2021
Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer Therapy
14 July 2021
Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
11 May 2021
Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
08 February 2021
Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline
12 January 2021
Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time